The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks end with modest gain, but down on week overall

Fri, 26th Sep 2014 16:48

UK stocks ended the final session of the week with a modest rise, although on the week the index was significantly lower.The FTSE 100 closed 9.68 points higher at 6,649.39.Markets are concerned about mounting geopolitical tensions, with the government due to take a vote on whether to participate in a war against the "Islamic State" on Friday evening.David Cameron and Ed Miliband took to the stands in the House of Commons on Friday morning in an attempt to persuade parliament to support airstrikes against Islamic State (IS) militants in Iraq.Cameron urged members to support military action in the region, underlining Britain's clear basis for action in international law, strengthened by a direct request for British intervention made by the Iraqi government.The Prime Minister also highlighted the international coalition's need for Britain's unique military and intelligence capabilities in order to fight the Islamist militant group."Is there a threat to the British people? The answer is yes," Cameron told parliament, saying he thought action would need to last "years" to be effective.Members are expected to vote in favour of entering the conflict.Soaring house prices could drive workers away from LondonLondon could be waving goodbye to a number of workers in the future, as the struggle to meet living costs in the British capital continues to rise.London's housing shortage could put the city's future at risk unless swift actions are taken to address one of the capital's chronic problems, research conducted by YouGov shows.Japanese CPI disappointsLooking abroad, Japanese consumer price inflation came in weaker than expected for August. The headline inflation rate slowed to a 3.3% year-on-year pace from 3.4%, with the ex-fresh food measure down to 3.1% from 3.3% (consensus: 3.2%)."Softer Japanese CPI data reinforced fears of more BoJ easing and hurt the JPY," analysts at UnicreditResearch said.Over in the States, gross domestic product (GDP) was revised higher in the second quarter, supported by better retail sales and foreign trade numbers.The US economy grew at a 4.6% annual rate in the three months to end of June, as predicted by analysts.Easyjet shares take off thanks to comments from JefferiesShares in Easyjet flew higher after Jefferies said the airline was situated to benefit from the recent problems with Air France-KLM, which has been forced to cancel numerous flights due to pilot strike action. The broker also predicted the group would have a positive finish to the year.Astrazeneca shares also squeezed higher after the company received positive feedback for Moventig, its new treatment for opioid-induced constipation.British Land shares were lifted by Societe Generale after it lifted its rating from 'hold' to 'buy'.Meanwhile, Sports Direct shares slumped into the red one day after its boss, Mike Ashley, yesterday surprised the market with the news it has completed a "put" option with Goldman Sachs in a complicated move that it said "reflects Sports Direct's growing relationship with Tesco and belief in Tesco's long-term future". The option relates to 23m Tesco shares.Tesco, together with its sector peers Sainsbury and Morrison, all continued to decline amid the growing price war amongst supermarkets.Slower-than-expected growth in its solutions division and challenging market conditions in its currency division have forced security documents designer and producer De La Rue to issue a profit warning, sending shares sharply lower.The FTSE 250 company said it expects operating profit and underlying profit before tax for the year to be £20m lower than originally estimated.Market MoverstechMARK 2,810.43 +0.37%FTSE 100 6,649.39 +0.15%FTSE 250 15,383.69 -0.27%FTSE 100 - RiserseasyJet (EZJ) 1,393.00p +3.19%St James's Place (STJ) 739.00p +2.78%British Land Co (BLND) 706.00p +2.10%Fresnillo (FRES) 761.50p +1.80%Shire Plc (SHP) 5,330.00p +1.72%ARM Holdings (ARM) 919.00p +1.66%Admiral Group (ADM) 1,253.00p +1.62%International Consolidated Airlines Group SA (CDI) (IAG) 370.70p +1.51%Hammerson (HMSO) 571.50p +1.51%Intu Properties (INTU) 330.50p +1.47%FTSE 100 - FallersSainsbury (J) (SBRY) 250.10p -3.06%Sports Direct International (SPD) 620.50p -2.67%Morrison (Wm) Supermarkets (MRW) 171.00p -1.78%Imperial Tobacco Group (IMT) 2,647.00p -1.78%IMI (IMI) 1,244.00p -1.66%Petrofac Ltd. (PFC) 1,010.00p -1.08%CRH (CRH) 1,389.00p -1.00%BG Group (BG.) 1,127.50p -0.97%TUI Travel (TT.) 387.50p -0.95%3i Group (III) 384.60p -0.88%FTSE 250 - RisersSupergroup (SGP) 1,136.00p +4.22%Fidessa Group (FDSA) 2,303.00p +3.00%Betfair Group (BET) 1,172.00p +2.99%Pets at Home Group (PETS) 176.00p +2.92%Evraz (EVR) 127.10p +2.92%Zoopla Property Group (WI) (ZPLA) 234.90p +2.76%SEGRO (SGRO) 365.40p +2.50%Millennium & Copthorne Hotels (MLC) 556.00p +2.39%Balfour Beatty (BBY) 224.90p +2.13%Capital & Counties Properties (CAPC) 332.40p +2.03%FTSE 250 - FallersDe La Rue (DLAR) 504.00p -33.60%Greencore Group (GNC) 240.80p -4.82%Ocado Group (OCDO) 267.40p -3.67%Daejan Holdings (DJAN) 4,878.00p -3.31%Hochschild Mining (HOC) 139.70p -2.92%Vesuvius (VSVS) 452.50p -2.88%Synthomer (SYNT) 215.00p -2.80%Playtech (PTEC) 716.00p -2.78%African Barrick Gold (ABG) 207.50p -2.72%Soco International (SIA) 372.40p -2.69%
More News
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.